| 39.59 Data as of May 17 |  +0.045 / +0.11%Today’s Change | 17.06 Today|||52-Week Range 42.41 | +77.99% Year-to-Date |
| Elan in Royalty Deal with THRX - Analyst Blog May 14 / Zacks.com | Stock Futures Lower Ahead of Retail Sales May 13 / TheStreet.com |
| Glaxo/THRX's Breo Ellipta Gets FDA Nod - Analyst Blog May 13 / Zacks.com | Stocks to Watch: Elan, Theravance, Take-Two May 13 / TheStreet.com |
| Morning Briefing: 10 Things You Should Know May 13 / TheStreet.com |
| Previous close | 39.54 |
| Today’s open | 39.46 |
| Day’s range | 39.02 - 39.73 |
| Volume | 810,013 |
| Average volume (3 months) | 1,527,241 |
| Market cap | $3.9B |
| Dividend yield | -- |
| Earnings growth (last year) | +85.82% |
| Earnings growth (this year) | -887.00% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +453.84% |
| P/E ratio | NM |
| Price/Sales | 14.89 |
| Price/Book | 25.12 |
| Today’s change | Today’s % change | |
|---|---|---|
| ENDPEndo Health Solution... | +1.07 | +3.21% |
| ALKSAlkermes Plc | +1.36 | +4.48% |
| SLXPSalix Pharmaceutical... | +0.09 | +0.15% |
| MDVNMedivation Inc | -0.76 | -1.57% |
| Next reporting date | July 25, 2013 |
| EPS forecast (this quarter) | -$0.53 |
| Annual revenue (last year) | $135.8M |
| Annual profit (last year) | -$18.5M |
| Net profit margin | -13.66% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Rick E. Winningham, MBA |
CFO, Senior VP & Head-Investor Relations Michael W. Aguiar, MBA |
Corporate headquarters South San Francisco, California |
.
